Type 1 piliated uropathogenic Escherichia coli hijack the host immune response by binding to CD14

  1. Kathrin Tomasek  Is a corresponding author
  2. Alexander Leithner
  3. Ivana Glatzova
  4. Michael Sebastian Lukesch
  5. Calin C Guet  Is a corresponding author
  6. Michael Sixt  Is a corresponding author
  1. Institute of Science and Technology Austria, Austria
  2. VALANX Biotech GmbH, Austria

Abstract

A key attribute of persistent or recurring bacterial infections is the ability of the pathogen to evade the host's immune response. Many Enterobacteriaceae express type 1 pili, a pre-adapted virulence trait, to invade host epithelial cells and establish persistent infections. However, the molecular mechanisms and strategies by which bacteria actively circumvent the immune response of the host remain poorly understood. Here, we identified CD14, the major co-receptor for lipopolysaccharide detection, on mouse dendritic cells as a binding partner of FimH, the protein located at the tip of the type 1 pilus of Escherichia coli. The FimH amino acids involved in CD14 binding are highly conserved across pathogenic and non-pathogenic strains. Binding of the pathogenic strain CFT073 to CD14 reduced dendritic cell migration by overactivation of integrins and blunted expression of co-stimulatory molecules by overactivating the NFAT pathway, both rate-limiting factors of T cell activation. This response was binary at the single cell level, but averaged in larger populations exposed to both piliated and non-piliated pathogens, presumably via the exchange of immunomodulatory cytokines. While defining an active molecular mechanism of immune evasion by pathogens, the interaction between FimH and CD14 represents a potential target to interfere with persistent and recurrent infections, such as urinary tract infections or Crohn's disease.

Data availability

All data are included in the manuscript. Source data are uploaded with this manuscript.

Article and author information

Author details

  1. Kathrin Tomasek

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    For correspondence
    kathrin.tomasek@epfl.ch
    Competing interests
    Kathrin Tomasek, is an inventor on patent application 21170193.3 (Methods determining the potential of drug for treating bacterial infections and composition for treating bacterial infections").".
  2. Alexander Leithner

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Competing interests
    No competing interests declared.
  3. Ivana Glatzova

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Competing interests
    No competing interests declared.
  4. Michael Sebastian Lukesch

    VALANX Biotech GmbH, Klosterneuburg, Austria
    Competing interests
    Michael Sebastian Lukesch, is affiliated with VALANX Biotech GmbH. The author has no financial interests to declare.Is an inventor on patent application 21170193.3 (Methods determining the potential of drug for treating bacterial infections and composition for treating bacterial infections").".
  5. Calin C Guet

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    For correspondence
    calin.guet@ist.ac.at
    Competing interests
    Calin C Guet, is an inventor on patent application 21170193.3 (Methods determining the potential of drug for treating bacterial infections and composition for treating bacterial infections").".
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6220-2052
  6. Michael Sixt

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    For correspondence
    sixt@ist.ac.at
    Competing interests
    Michael Sixt, is an inventor on patent application 21170193.3 (Methods determining the potential of drug for treating bacterial infections and composition for treating bacterial infections").".
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6620-9179

Funding

European Research Council (CoG 724373)

  • Michael Sixt

Austrian Science Fund (FWF P29911)

  • Michael Sixt

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Ivan Zanoni, Harvard Medical School, United States

Ethics

Animal experimentation: All animal experiments are in accordance with the Austrian law for animal experiments. Permission was granted by the Austrian Federal Ministry of Science, Research and Economy (identification code: BMWFW 66.018/0010-WF/V/3b/2016). Mice were bred and maintained at the local animal facility in accordance IST Austria Ethical Committee or purchased from Charles River and maintained at the local animal facility in accordance with IST Austria Ethical Committee.

Version history

  1. Preprint posted: October 18, 2021 (view preprint)
  2. Received: March 26, 2022
  3. Accepted: July 19, 2022
  4. Accepted Manuscript published: July 26, 2022 (version 1)
  5. Version of Record published: August 8, 2022 (version 2)

Copyright

© 2022, Tomasek et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,468
    views
  • 329
    downloads
  • 2
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kathrin Tomasek
  2. Alexander Leithner
  3. Ivana Glatzova
  4. Michael Sebastian Lukesch
  5. Calin C Guet
  6. Michael Sixt
(2022)
Type 1 piliated uropathogenic Escherichia coli hijack the host immune response by binding to CD14
eLife 11:e78995.
https://doi.org/10.7554/eLife.78995

Share this article

https://doi.org/10.7554/eLife.78995

Further reading

    1. Evolutionary Biology
    2. Immunology and Inflammation
    Mark S Lee, Peter J Tuohy ... Michael S Kuhns
    Research Advance

    CD4+ T cell activation is driven by five-module receptor complexes. The T cell receptor (TCR) is the receptor module that binds composite surfaces of peptide antigens embedded within MHCII molecules (pMHCII). It associates with three signaling modules (CD3γε, CD3δε, and CD3ζζ) to form TCR-CD3 complexes. CD4 is the coreceptor module. It reciprocally associates with TCR-CD3-pMHCII assemblies on the outside of a CD4+ T cells and with the Src kinase, LCK, on the inside. Previously, we reported that the CD4 transmembrane GGXXG and cytoplasmic juxtamembrane (C/F)CV+C motifs found in eutherian (placental mammal) CD4 have constituent residues that evolved under purifying selection (Lee et al., 2022). Expressing mutants of these motifs together in T cell hybridomas increased CD4-LCK association but reduced CD3ζ, ZAP70, and PLCγ1 phosphorylation levels, as well as IL-2 production, in response to agonist pMHCII. Because these mutants preferentially localized CD4-LCK pairs to non-raft membrane fractions, one explanation for our results was that they impaired proximal signaling by sequestering LCK away from TCR-CD3. An alternative hypothesis is that the mutations directly impacted signaling because the motifs normally play an LCK-independent role in signaling. The goal of this study was to discriminate between these possibilities. Using T cell hybridomas, our results indicate that: intracellular CD4-LCK interactions are not necessary for pMHCII-specific signal initiation; the GGXXG and (C/F)CV+C motifs are key determinants of CD4-mediated pMHCII-specific signal amplification; the GGXXG and (C/F)CV+C motifs exert their functions independently of direct CD4-LCK association. These data provide a mechanistic explanation for why residues within these motifs are under purifying selection in jawed vertebrates. The results are also important to consider for biomimetic engineering of synthetic receptors.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Jean-David Larouche, Céline M Laumont ... Claude Perreault
    Research Article

    Transposable elements (TEs) are repetitive sequences representing ~45% of the human and mouse genomes and are highly expressed by medullary thymic epithelial cells (mTECs). In this study, we investigated the role of TEs on T-cell development in the thymus. We performed multiomic analyses of TEs in human and mouse thymic cells to elucidate their role in T-cell development. We report that TE expression in the human thymus is high and shows extensive age- and cell lineage-related variations. TE expression correlates with multiple transcription factors in all cell types of the human thymus. Two cell types express particularly broad TE repertoires: mTECs and plasmacytoid dendritic cells (pDCs). In mTECs, transcriptomic data suggest that TEs interact with transcription factors essential for mTEC development and function (e.g., PAX1 and REL), and immunopeptidomic data showed that TEs generate MHC-I-associated peptides implicated in thymocyte education. Notably, AIRE, FEZF2, and CHD4 regulate small yet non-redundant sets of TEs in murine mTECs. Human thymic pDCs homogenously express large numbers of TEs that likely form dsRNA, which can activate innate immune receptors, potentially explaining why thymic pDCs constitutively secrete IFN ɑ/β. This study highlights the diversity of interactions between TEs and the adaptive immune system. TEs are genetic parasites, and the two thymic cell types most affected by TEs (mTEcs and pDCs) are essential to establishing central T-cell tolerance. Therefore, we propose that orchestrating TE expression in thymic cells is critical to prevent autoimmunity in vertebrates.